Objective
To analyze the expression of the antiapoptotic gene bcl-xL in human pancreatic cancer and to correlate the results with clinical patient parameters.
Summary Background Data
Bcl-xL belongs to the bcl-2-related gene family and acts as a broad antiapoptotic factor to extend both normal and tumor cell survival. Recent findings indicate that tumor cell death induced by chemotherapy and radiotherapy is mediated by the activation of apoptosis. The fact that pancreatic cancer has an extremely malignant potential and that it is resistant to most anticancer treatment modalities suggests that mechanisms are activated that increase the viability of pancreatic cancer cells.
Methods
Seventy-four pancreatic cancer tissue samples were obtained from 32 female and 42 male patients undergoing surgery for exocrine pancreatic cancer. Normal human pancreatic tissue samples were available from 11 organ donors and 4 patients without pancreatic disease. The levels of bcl-xL mRNA expression were analyzed by Northern blot analysis. The exact site of bcl-xL mRNA transcription was determined by nonradioactive in situ hybridization. In addition, immunohistochemistry using specific polyclonal antibodies was used to localize the protein.
Results
Northern blot analysis indicated that, in comparison with the normal pancreas, bcl-xL mRNA was markedly overexpressed in 54% of the pancreatic cancer samples. Densitometric analysis revealed that pancreatic adenocarcinomas exhibited a mean 3.4-fold increase (p < 0.01) in bcl-xL mRNA levels in comparison with normal controls. With in situ hybridization, bcl-xL mRNA was found to be highly expressed in the cancer cells of tumor samples that exhibited increased mRNA expression by Northern blot analysis. Immunohistochemical analysis revealed bcl-x immunostaining in 88% of the cancer samples. Correlation of the molecular data with clinical patient parameters revealed that patients whose tumors exhibited no, faint, or weak bcl-xL expression lived significantly longer after tumor resection (median 12 months) than patients whose tumors exhibited moderate bcl-xL mRNA expression (median 5 months) (p < 0.05). However, 5 patients whose tumors exhibited intense bcl-xL mRNA expression tended to live longer (median 14 months).
Conclusion
Enhanced expression of the antiapoptotic gene bcl-xL in pancreatic cancer and its association with shorter patient survival suggests that this factor may enhance the viability of pancreatic cancer cells in vivo. Inhibition of apoptotic pathways might be one of the reasons why pancreatic cancer shows only limited sensitivity to anticancer treatment.
Although pancreatic cancer has an incidence of about 10 cases/100,000 persons, it is still the fourth or fifth leading cause of cancer-related death in Western industrialized countries.' Most cases are diagnosed in advanced tumor stages, and therefore only a few patients qualify for tumor 24 resection. -In most patients the tumor has already metastasized at the time of diagnosis into lymph nodes or distant organs, or the primary tumor has infiltrated the large retroperitoneal vessels, making tumor resection impossible without major vessel resection and substitution.
In addition to the extensive progression in local tumor then prehybridized, hybridized, and washed under conditions appropriate for the alpha-32P-labeled antisense riboprobe (bcl-xL) or cDNA probe (7S), as previously described in detail.5 '25'26 For the riboprobe, the blots were prehybridized for 6 hours in 50% formamide, 0.5% sodium dodecyl sulfate (SDS), 5 X SSC (sodium chloride/sodium citrate buffer), 5 X Denhardt's solution (1 X Denhardt's solution = 0.02% ficoll, 0.02% polyvinylpyrrolidone, and 0.02% bovine serum albumin), 250 mg/l salmon sperm DNA, and 50 mmol/l sodium phosphate buffer (pH 6.5). The blots were then hybridized for 18 hours at 65°C in the presence of 1 X 106 cpm/ml of the labeled antisense riboprobe, washed twice at 65°C in a solution containing 1 X SSPE (150 mmol/l NaCl, 10 mmol/l NaH2PO4, and 1 mmol/l EDTA) and 0.5% SDS, and washed twice at 65°C in a solution containing 0.1 X SSPE and 0.5% SDS.5'25 '26 For the 7S cDNA probes, prehybridization was carried out for 4 to 8 hours at 42°C in a buffer that contained 50% formamide, 1% SDS, 0.75 mol/m NaCl, 5 mmol/l EDTA, 5 X Denhardt's solution, 100 mg/l salmon sperm DNA, 10% dextran sulfate, and 50 mmol/l sodium phosphate buffer, pH 7.4. Hybridization was carried out at 42°C for 18 hours after adding 1 X 105 cpm/ml of the 32P-labeled 7S cDNA probe to the prehybridization buffer. After the hybridization solution was removed, the blots were washed under stringent conditions consisting of two rinses in 2 X SSC at room temperature followed by three washings of 20 minutes each at 55°C in 0.2 X SSC and 2% SDS.
Blots were then exposed to Fuji x-ray films with intensifying screens (DuPont) at -80°C, and the intensity of the radiographic bands was quantified by video image analysis (Image-Pro plus for Windows, Media Cybernetics, Silver Spring, MD), as previously reported.5 '27 For statistical analysis the ratio between the bcl-xL mRNA signal and the corresponding 7S signal was calculated for each sample.
In Situ Hybridization
In situ hybridization was performed as previously reported.5'28 Briefly, using consecutive tissue slides, one slide was incubated with the digoxigenin (DIG)-labeled antisense riboprobe, and simultaneously the other was incubated with the corresponding sense probe under the same incubation conditions. The tissue sections (3 ,um) were deparaffinized, rehydrated with 1 X phosphate-buffered saline (PBS) and incubated in 0.2 mol/l HCI for 20 minutes at room temperature. After the slides were rinsed in 2 X SSC, the sections were treated with proteinase K (Boehringer Mannheim, Mannheim, Germany) at a concentration of 20 jig/ml for 15 minutes at 37°C. After postfixation with 4% paraformaldehyde in PBS (5 minutes) and washing in 2 X SSC, the samples were prehybridized at 590C for at least 2 hours in 50% formamide (v/v), 4 X SSC, 2 X Denhardt's reagent, and 250 ,ug RNA/ml. Hybridization was performed overnight at 59°C in 50% (v/v) formamide, 4 X SSC, 2 X Denhardt's reagent, 500 jig RNA/ml, and 10% dextran sulfate (w/v). The final concentrations of the DIG-labeled probes were approximately 2.5 ng/,ul. After hybridization, excess probe was removed by washing the slides in 2 X SSC and by RNase treatment: 100 U/ml RNase TI (Boehringer Mannheim) and 0.2 jig/ml RNase (DNase-free) (Boehringer Mannheim) at 37°C for 30 minutes. After washing in 2 X SSC for 20 minutes at 63°C, and in 0.14 X SSC and 30% formamide at 63°C for 20 minutes, the samples were incubated with the antidigoxigenin antibody conjugated with alkaline phosphatase (Boehringer Mannheim). For the final color reaction, 5-bromo-4-chloro-3-indolyl phosphate and nitro blue tetrazolium (Sigma, Buchs, Switzerland) were used.5 '28 Evaluation of the in situ hybridization results was performed semiquantitatively by two independent observers blinded to the patients' status.5'28 According to the intensity of specific hybridization signals, the expression levels of bcl-xL mRNA were classified as absent/faint (-), weak (+), moderate (+ +) and intense (+ + +).
Probe Synthesis for Northern Blot Analysis and In Situ Hybridization
Riboprobes of bcl-xL were used both in Northern blot analysis and in in situ hybridization. The bcl-xL cRNA probe consisted of a Clal/Xba I fragment of human bcl-xL cDNA prepared by reverse transcriptase polymerase chain 23 reaction. 3 For in situ hybridization, the bcl-xL cRNA probe was labeled with digoxigenin.5'28 After linearization, the cDNA was transcribed using the Ribomax System (Promega). The transcription resulted in digoxigenin-labeled antisense riboprobe specific for the bcl-xL mRNA. The corresponding sense probe was prepared in an analogous manner. For in situ hybridization, the sense and antisense probes were shortened to a length of about 150 bases and stored in diethylpyrocarbonate-treated water at -70°C until further use. 5 
RESULTS

Northern Blot Analysis of bcl-xL
Northern blot analysis using 20 ,ug total pancreatic RNA was carried out to determine bcl-xL mRNA expression in the normal and the cancerous pancreas. In all normal pancreatic tissue samples, bcl-xL mRNA expression was present at low levels (Fig. 1) . In some normal pancreatic tissue samples, the 3.0 kb bcl-xL mRNA transcript was faint and was visible only on the original autoradiographs. No differences in bcl-xL mRNA levels were found between the organ donor pancreases and the pancreases of patients in whom pancreatic resection was done as an extension of another intraabdominal resection. In contrast, hybridization signals of bcl-xL mRNA were markedly higher in many pancreatic cancer samples than in normal controls (see Fig.   1 ). Bcl-xL mRNA levels were In contrast, 61% (45/74) of the pancreatic cancer samples exhibited greater bcl-xL mRNA stalning than in the normal controls (Fig. 2B) (Fig. 2D) . In 84% (62/74) of the pancreatic cancer samples, bcl-x immunoreactivity was stronger than in the control samples. In the cancer tissues, 39% (29/74), 31% (23/74), and 18% (13/4) had low, medium, and high immunoreactivity staining scores, respectively. Nine of 74 (12%) pancreatic cancer samples were devoid of any bcl-x immunoreactivity. Normal pancreatic tissue regions around the cancer mass exhibited an immunohistochemical staining pattern comparable to that of the normal controls. However, regions adjacent to the pancreatic cancer mass in which chronic pancreatitis-like morphologic changes were present showed weak to moderate bcl-x immunoreactivity in the remaining ductal and acinar cells. In contrast, there was no bcl-x immunostaining in the connective tissue and in fibroblasts in the pancreatic cancer tissues.
Association of Immunohistochemical and In Situ Hybridization Findings With Clinicopathologic Parameters
To determine whether the expression of bcl-xL mRNA or the presence of bcl-x in pancreatic cancer cells is of clinical significance for the course of the disease, the immunohistochemical and in situ hybridization data were correlated with clinical parameters such as gender, age, tumor differentiation, tumor stage, and survival after tumor resection. Six patients with stage IV disease and one patient who died early after surgery were excluded from the survival analysis. We excluded patients with stage IV disease because no tumor resection was performed (except in one patient), and therefore the survival prognosis was different from that of patients who underwent resection.
We found no relation between the presence of either bcl-x immunoreactivity or bcl-xL mRNA expression in pancreatic cancer cells and the patient's age, gender, tumor differentiation, tumor stage, or tumor size ( Table 1) .
The survival data were plotted according to the method of Kaplan and Meier. Statistical analysis of survival after surgery and bcl-xL mRNA expression levels was carried out by the log-rank test.
Patients whose tumors exhibited moderate bcl-xL mRNA expression levels lived significantly shorter (median 5 months) than did patients with weak, faint, or absent bcl-xL mRNA expression levels in their tumors (median 12 months) (Fig. 3) . In five patients, strong bcl-xL mRNA expression was found in the tumors. However, when survival analysis was done in these patients, they tended to live longer (median 14 months, no statistical analysis done because of low sample number) than patients with moderate bcl-xL mRNA expression levels.
DISCUSSION
The bcl-x gene was identified in 1993 by low-stringency hybridization of chicken lymphoid cells with a murine bcl-2 cDNA.23 It shows 44% homology with bcl-2 and mediates similar functions. In humans, two subforms of bcl-x (bcl-xL Follow up (months) Figure 3 . Survival curve. Kaplan-Meier plot of the survival period after surgery in patients whose tumors exhibited moderate bcl-xL mRNA expression (n = 13, broken line) vs. patients whose tumors had absent, faint, or weak bcl-xL mRNA expression (n = 49, solid line). Log-rank analysis of the survival periods after surgery indicated a significant difference (p < 0.05). 
